At Spruce, we are dedicated to finding new ways to treat rare endocrine disorders. Our team is focused on advancing the development of novel therapies that improve outcomes for people with classic congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS), and other rare endocrine disorders. We are led by seasoned life sciences professionals who have significant experience in developing and commercializing orphan drug therapies.

With tildacerfont, we aim to advance the treatment paradigm for classic CAH patients with a non-steroidal approach designed to offer improved disease control and reduced glucocorticoid steroid burden in patients. We also aim to develop a novel therapeutic option for women and girls suffering from a rare form of PCOS driven by adrenal dysfunction.

We are currently conducting clinical trials evaluating tildacerfont for the treatment of adults with classic CAH. We plan to initiate Phase 2 trials in pediatric classic CAH and PCOS patients in 2021.